Danshenol A Alleviates Hypertension-Induced Cardiac Remodeling by Ameliorating Mitochondrial Dysfunction and Suppressing Reactive Oxygen Species Production

Abstract

Current therapeutic approaches have a limited effect on cardiac remodeling, which is characteristic of cardiac fibrosis and myocardial hypertrophy. In this study, we examined whether Danshenol A (DA), an active ingredient extracted from the traditional Chinese medicine Radix Salviae, can attenuate cardiac remodeling and clarified the underlying mechanisms. Using the spontaneously hypertensive rat (SHR) as a cardiac remodeling model, DA ameliorated blood pressure, cardiac injury, and myocardial collagen volume and improved cardiac function. Bioinformatics analysis revealed that DA might attenuate cardiac remodeling through modulating mitochondrial dysfunction and reactive oxygen species. DA repaired the structure/function of the mitochondria, alleviated oxidative stress in the myocardium, and restored apoptosis of cardiomyocytes induced by angiotensin II. Besides, DA inhibited mitochondrial redox signaling pathways in both the myocardium and cardiomyocytes. Thus, our study suggested that DA attenuates cardiac remodeling induced by hypertension through modulating mitochondrial dysfunction and reactive oxygen species.

MicroRNAs Regulating Mitochondrial Function in Cardiac Diseases

“…Under normal physiological conditions, 90% of the energy required by the heart is derived from mitochondrial OXPHOS, and normal mitochondrial function is a necessary prerequisite for the maintenance of the heart pumping function. Recently, increasing data have shown that mitochondrial dysfunction is involved in the occurrence of cardiac diseases, such as cardiac hypertrophy, myocardial fibrosis (Chen et al, 2019), diabetic cardiomyopathy (Gollmer et al, 2020), and heart failure (Kumar et al, 2019). Accumulating evidence has also suggested that targeting mitochondrial function may represent a promising potential therapeutic strategy for addressing heart failure (Brown et al, 2017).…”

Network pharmacology and molecular docking to explore the pharmacological mechanism of Yifei Tongluo granules in treating idiopathic pulmonary fibrosis: A review

“…[23] DA ameliorates myocardial fibrosis by inhibiting mitochondrial dysfunction and reducing reactive oxygen species production. [24] The biological effects exhibited by these compounds suggest that YTG may act as an antifibrotic agent through multiple mechanisms.…”

S-Doped carbonized polymer dots inhibit early myocardial fibrosis by regulating mitochondrial function

“…Mitochondria are the necessary energy supply organelles to maintain the normal morphology and function of cardiomyocytes. 22,23 The ATP assay showed that ISO inhibited the expression of ATP, while it could be alleviated by S-CPDs (Fig. 3a).…”